Clinical Neurogenetics: Amyotrophic Lateral Sclerosis

Neurologic Clinics

Volumn 31, Issue 4, 2013, Pages 929-950

  Harms, Matthew B ^a   Baloh, Robert H ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

ALS; Amyotrophic lateral sclerosis; Genetics; Phenotypes

Indexed keywords

ANGIOGENIN; ATAXIN 1; ATAXIN 2; CELL PROTEIN; CHOLESTANETRIOL 26 MONOOXYGENASE; COPPER ZINC SUPEROXIDE DISMUTASE; ELONGATION PROTEIN 3; HELICASE; OPTINEURIN; PROFILIN; PROFILIN I; PROTEIN DPP6; PROTEIN UNC13A; PROTEIN VAPB; RILUZOLE; RNA BINDING PROTEIN; RNA HELICASE; RNA POLYMERASE; SENATAXIN; SYNAPTOBREVIN; TAR DNA BINDING PROTEIN; UBIQUILIN 2; UBIQUITIN; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; C9ORF72 GENE; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME 9P; CLINICAL FEATURE; DISEASE CLASSIFICATION; ELECTROMYOGRAPHY; FAMILY HISTORY; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; PENETRANCE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME;

ALS; AMYOTROPHIC LATERAL SCLEROSIS; GENETICS; PHENOTYPES;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS;

EID: 84886405547     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.05.003     Document Type: Review

References (188)

1. Geser F., Martinez-Lage M., Robinson J., et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009, 66(2):180-189.
2. Geser F., Brandmeir N.J., Kwong L.K., et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol 2008, 65(5):636-641.
3. Isaacs J.D., Dean A.F., Shaw C.E., et al. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder?. JNeurol Neurosurg Psychiatry 2007, 78(7):750-753.
4. Scotton W.J., Scott K.M., Moore D.H., et al. Prognostic categories for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012, 13(6):502-508.
5. Lomen-Hoerth C., Murphy J., Langmore S., et al. Are amyotrophic lateral sclerosis patients cognitively normal?. Neurology 2003, 60(7):1094-1097.
6. Ringholz G.M., Appel S.H., Bradshaw M., et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005, 65(4):586-590.
7. Gilbert R.M., Fahn S., Mitsumoto H., et al. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 2010, 25(12):1868-1875.
8. Pinkhardt E.H., Sperfeld A.D., Gdynia H.J., et al. The combination of dopa-responsive parkinsonian syndrome and motor neuron disease. Neurodegener Dis 2009, 6(3):95-101.
9. Hammad M., Silva A., Glass J., et al. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 2007, 69(24):2236-2242.
10. Luigetti M., Conte A., Del Grande A., et al. Sural nerve pathology in ALS patients: a single-centre experience. Neurol Sci 2012, 33(5):1095-1099.
11. Brooks B.R., Miller R.G., Swash M., et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1(5):293-299.
12. de Carvalho M., Dengler R., Eisen A., et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008, 119(3):497-503.
13. Kim W.K., Liu X., Sandner J., et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009, 73(20):1686-1692.
14. Kosaka T., Fu Y.J., Shiga A., et al. Primary lateral sclerosis: upper-motor-predominant amyotrophic lateral sclerosis with frontotemporal lobar degeneration-immunohistochemical and biochemical analyses of TDP-43. Neuropathology 2012, 32(4):373-384.
15. Pamphlett R. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2010, 74(23):1926. [author reply: 1926-7].
16. Visser J., van den Berg-Vos R.M., Franssen H., et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 2007, 64(4):522-528.
17. van Blitterswijk M., Vlam L., van Es M.A., et al. Genetic overlap between apparently sporadic motor neuron diseases. PLoS One 2012, 7(11):e48983.
18. Ringholz G.M., Greene S.R. The relationship between amyotrophic lateral sclerosis and frontotemporal dementia. Curr Neurol Neurosci Rep 2006, 6(5):387-392.
19. Fecto F., Siddique T. Making connections: pathology and genetics link amyotrophic lateral sclerosis with frontotemporal lobe dementia. JMol Neurosci 2011, 45(3):663-675.
20. Rosen A.D. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978, 35(10):638-642.
21. Dietrich-Neto F., Callegaro D., Dias-Tosta E., et al. Amyotrophic lateral sclerosis in Brazil: 1998 national survey. Arq Neuropsiquiatr 2000, 58(3A):607-615.
22. Haverkamp L.J., Appel V., Appel S.H. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995, 118(Pt 3):707-719.
23. Gordon P.H., Cheng B., Salachas F., et al. Progression in ALS is not linear but is curvilinear. JNeurol 2010, 257(10):1713-1717.
24. Murray B. Natural history and prognosis in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis 2006, 227-255. Taylor & Francis, New York. 1st edition. H.P. Mitsumoto, P.H. Gordon (Eds.).
25. Juergens S.M., Kurland L.T., Okazaki H., et al. ALS in Rochester, Minnesota, 1925-1977. Neurology 1980, 30(5):463-470.
26. Caroscio J.T., Mulvihill M.N., Sterling R., et al. Amyotrophic lateral sclerosis. Its natural history. Neurol Clin 1987, 5(1):1-8.
27. Lee C.T., Chiu Y.W., Wang K.C., et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. JEpidemiol 2013, 23(1):35-40.
28. Gordon P.H., Salachas F., Lacomblez L., et al. Predicting survival of patients with amyotrophic lateral sclerosis at presentation: a 15-year experience. Neurodegener Dis 2013, 12:81-90.
29. Czaplinski A., Yen A.A., Simpson E.P., et al. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?. Arch Neurol 2006, 63(8):1139-1143.
30. The Scottish Motor Neuron Disease Register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demography and clinical features of incident cases in 1989. JNeurol Neurosurg Psychiatry 1992, 55(7):536-541.
31. Chancellor A.M., Slattery J.M., Fraser H., et al. The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register. JNeurol 1993, 240(6):339-346.
32. Forbes R.B., Colville S., Cran G.W., et al. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease. JNeurol Neurosurg Psychiatry 2004, 75(12):1753-1755.
33. Gordon P.H., Salachas F., Bruneteau G., et al. Improving survival in a large French ALS center cohort. JNeurol 2012, 259(9):1788-1792.
34. Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012, (3). CD001447.
35. Annegers J.F., Appel S., Lee J.R., et al. Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985-1988. Arch Neurol 1991, 48(6):589-593.
36. McGuire V., Longstreth W.T., Koepsell T.D., et al. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology 1996, 47(2):571-573.
37. Traynor B.J., Codd M.B., Corr B., et al. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology 1999, 52(3):504-509.
38. Pradas J., Puig T., Rojas-Garcia R., et al. Amyotrophic lateral sclerosis in Catalonia: a population based study. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(4):278-283.
39. Bandettini di Poggio M., Sormani M.P., Truffelli R., et al. Clinical epidemiology of ALS in Liguria, Italy. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(1):52-57.
40. Abhinav K., Stanton B., Johnston C., et al. Amyotrophic lateral sclerosis in South-East England: a population-based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry). Neuroepidemiology 2007, 29(1-2):44-48.
41. Sajjadi M., Etemadifar M., Nemati A., et al. Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran. Eur J Neurol 2010, 17(7):984-989.
42. Vazquez M.C., Ketzoian C., Legnani C., et al. Incidence and prevalence of amyotrophic lateral sclerosis in Uruguay: a population-based study. Neuroepidemiology 2008, 30(2):105-111.
43. Johnston C.A., Stanton B.R., Turner M.R., et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. JNeurol 2006, 253(12):1642-1643.
44. McGuire Van L.M. Epidemiology of ALS. Amyotrophic lateral sclerosis 2006, 17-41. Taylor & Francis, New York. 1st edition. H.P. Mitsumoto, P.H. Gordon (Eds.).
45. Blasco H., Guennoc A.M., Veyrat-Durebex C., et al. Amyotrophic lateral sclerosis: a hormonal condition?. Amyotroph Lateral Scler 2012, 13(6):585-588.
46. Logroscino G., Traynor B.J., Hardiman O., et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. JNeurol Neurosurg Psychiatry 2008, 79(1):6-11.
47. Osler W. Heredity in progressive muscular atrophy as illustrated in Farr family of Vermont. Arch Med 1880, 4:316-320.
48. Byrne S., Elamin M., Bede P., et al. Absence of consensus in diagnostic criteria for familial neurodegenerative diseases. JNeurol Neurosurg Psychiatry 2012, 83(4):365-367.
49. Chio A., Borghero G., Pugliatti M., et al. Large proportion of amyotrophic lateral sclerosis cases in Sardinia due to a single founder mutation of the TARDBP gene. Arch Neurol 2011, 68(5):594-598.
50. Eisen A., Mezei M.M., Stewart H.G., et al. SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neurophysiology and ethical issues in management. Amyotroph Lateral Scler 2008, 9(2):108-119.
51. Byrne S., Walsh C., Lynch C., et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. JNeurol Neurosurg Psychiatry 2011, 82(6):623-627.
52. Byrne S., Bede P., Elamin M., et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011, 12(3):157-159.
53. Al-Chalabi A., Lewis C.M. Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 2011, 71(4):281-288.
54. Millecamps S., Salachas F., Cazeneuve C., et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. JMed Genet 2010, 47(8):554-560.
55. Gellera C., Tiloca C., Del Bo R., et al. Ubiquilin 2 mutations in Italian patients with amyotrophic lateral sclerosis and frontotemporal dementia. JNeurol Neurosurg Psychiatry 2013, 84(2):183-187.
56. Morita M., Al-Chalabi A., Andersen P.M., et al. Alocus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006, 66(6):839-844.
57. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72(2):245-256.
58. Renton A.E., Majounie E., Waite A., et al. Ahexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72(2):257-268.
59. Harms M.B., Cady J., Zaidman C., et al. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiol Aging 2013, 34(9):2234.e13-2234.e19.
60. van Blitterswijk M., Dejesus-Hernandez M., Rademakers R. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?. Curr Opin Neurol 2012, 25(6):689-700.
61. Majounie E., Renton A.E., Mok K., et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012, 11(4):323-330.
62. Levine T.P., Daniels R.D., Gatta A.T., et al. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 2013, 29(4):499-503.
63. Zhang D., Iyer L.M., He F., et al. Discovery of novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front Genet 2012, 3:283.
64. van der Zee J., Gijselinck I., Dillen L., et al. Apan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat 2013, 34(2):363-373.
65. Echeverria G.V., Cooper T.A. RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res 2012, 1462:100-111.
66. Mori K., Weng S.M., Arzberger T., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339(6125):1335-1338.
67. Ash P.E., Bieniek K.F., Gendron T.F., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77(4):639-646.
68. Harms M., Benitez B.A., Cairns N., et al. C9orf72 hexanucleotide repeat expansions in clinical Alzheimer disease. JAMA Neurol 2013, 1-6.
69. Majounie E., Abramzon Y., Renton A.E., et al. Repeat expansion in C9ORF72 in Alzheimer's disease. NEngl J Med 2012, 366(3):283-284.
70. Lindquist S., Duno M., Batbayli M., et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet 2013, 83(3):279-283.
71. Rollinson S., Halliwell N., Young K., et al. Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer's disease. Neurobiol Aging 2012, 33(8):1846.e5-1846.e6.
72. Rosen D.R., Siddique T., Patterson D., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362(6415):59-62.
73. Chio A., Traynor B.J., Lombardo F., et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology 2008, 70(7):533-537.
74. Battistini S., Giannini F., Greco G., et al. SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study. JNeurol 2005, 252(7):782-788.
75. Ratovitski T., Corson L.B., Strain J., et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum Mol Genet 1999, 8(8):1451-1460.
76. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. JCell Biol 2009, 187(6):761-772.
77. Wicks P., Abrahams S., Papps B., et al. SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. JNeurol 2009, 256(2):234-241.
78. Cudkowicz M.E., McKenna-Yasek D., Chen C., et al. Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol 1998, 43(6):703-710.
79. Cudkowicz M.E., McKenna-Yasek D., Sapp P.E., et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997, 41(2):210-221.
80. Del Grande A., Conte A., Lattante S., et al. D11Y SOD1 mutation and benign ALS: a consistent genotype-phenotype correlation. JNeurol Sci 2011, 309(1-2):31-33.
81. Andersen P.M., Forsgren L., Binzer M., et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996, 119(Pt 4):1153-1172.
82. Neumann M., Sampathu D.M., Kwong L.K., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314(5796):130-133.
83. Sreedharan J., Blair I.P., Tripathi V.B., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319(5870):1668-1672.
84. Gitcho M.A., Baloh R.H., Chakraverty S., et al. TDP-43 A315T mutation in familial motor neuron disease. Ann Neurol 2008, 63(4):535-538.
85. Kabashi E., Valdmanis P.N., Dion P., et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008, 40(5):572-574.
86. Borroni B., Bonvicini C., Alberici A., et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat 2009, 30(11):E974-E983.
87. Ayala Y.M., Pagani F., Baralle F.E. TDP43 depletion rescues aberrant CFTR exon 9 skipping. FEBS Lett 2006, 580(5):1339-1344.
88. Ayala Y.M., Pantano S., D'Ambrogio A., et al. Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function. JMol Biol 2005, 348(3):575-588.
89. Ling S.C., Albuquerque C.P., Han J.S., et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci USA 2010, 107(30):13318-13323.
90. Corcia P., Valdmanis P., Millecamps S., et al. Phenotype and genotype analysis in amyotrophic lateral sclerosis with TARDBP gene mutations. Neurology 2012, 78(19):1519-1526.
91. Quadri M., Cossu G., Saddi V., et al. Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics 2011, 12(3):203-209.
92. Rayaprolu S., Fujioka S., Traynor S., et al. TARDBP mutations in Parkinson's disease. Parkinsonism Relat Disord 2013, 19(3):312-315.
93. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323(5918):1205-1208.
94. Vance C., Rogelj B., Hortobagyi T., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323(5918):1208-1211.
95. Belzil V.V., Valdmanis P.N., Dion P.A., et al. Mutations in FUS cause FALS and SALS in French and French Canadian populations. Neurology 2009, 73(15):1176-1179.
96. Damme P.V., Goris A., Race V., et al. The occurrence of mutations in FUS in a Belgian cohort of patients with familial ALS. Eur J Neurol 2010, 17(5):754-756.
97. Waibel S., Neumann M., Rosenbohm A., et al. Truncating mutations in FUS/TLS give rise to a more aggressive ALS-phenotype than missense mutations: a clinico-genetic study in Germany. Eur J Neurol 2013, 20(3):540-546.
98. Suzuki N., Aoki M., Warita H., et al. FALS with FUS mutation in Japan, with early onset, rapid progress and basophilic inclusion. JHum Genet 2010, 55(4):252-254.
99. Tsai C.P., Soong B.W., Lin K.P., et al. FUS, TARDBP, and SOD1 mutations in a Taiwanese cohort with familial ALS. Neurobiol Aging 2011, 32(3):553.e13-553.e21.
100. Zou Z.Y., Cui L.Y., Sun Q., et al. De novo FUS gene mutations are associated with juvenile-onset sporadic amyotrophic lateral sclerosis in China. Neurobiol Aging 2013, 34(4):1312.e1-1312.e8.
101. Drepper C., Herrmann T., Wessig C., et al. C-terminal FUS/TLS mutations in familial and sporadic ALS in Germany. Neurobiol Aging 2011, 32(3):548.e1-548.e4.
102. Lai S.L., Abramzon Y., Schymick J.C., et al. FUS mutations in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2011, 32(3):550.e1-550.e4.
103. Kwon M.J., Baek W., Ki C.S., et al. Screening of the SOD1, FUS, TARDBP, ANG, and OPTN mutations in Korean patients with familial and sporadic ALS. Neurobiol Aging 2012, 33(5):1017.e17-1017.e23.
104. DeJesus-Hernandez M., Kocerha J., Finch N., et al. De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat 2010, 31(5):E1377-E1389.
105. Chio A., Calvo A., Moglia C., et al. Ade novo missense mutation of the FUS gene in a "true" sporadic ALS case. Neurobiol Aging 2011, 32(3):553.e23-553.e26.
106. Couthouis J., Hart M.P., Shorter J., et al. Ayeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci USA 2011, 108(52):20881-20890.
107. Couthouis J., Hart M.P., Erion R., et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 2012, 21(13):2899-2911.
108. Dormann D., Rodde R., Edbauer D., et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J 2010, 29(16):2841-2857.
109. Hewitt C., Kirby J., Highley J.R., et al. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2010, 67(4):455-461.
110. Blair I.P., Williams K.L., Warraich S.T., et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. JNeurol Neurosurg Psychiatry 2010, 81(6):639-645.
111. Waibel S., Neumann M., Rabe M., et al. Novel missense and truncating mutations in FUS/TLS in familial ALS. Neurology 2010, 75(9):815-817.
112. Baumer D., Hilton D., Paine S.M., et al. Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS mutations. Neurology 2010, 75(7):611-618.
113. Huey E.D., Ferrari R., Moreno J.H., et al. FUS and TDP43 genetic variability in FTD and CBS. Neurobiol Aging 2012, 33(5). 1016.e9-17.
114. Parmalee N., Mirzozoda K., Kisselev S., et al. Genetic analysis of the FUS/TLS gene in essential tremor. Eur J Neurol 2013, 20(3):534-539.
115. Deng H.X., Chen W., Hong S.T., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477(7363):211-215.
116. Daoud H., Suhail H., Szuto A., et al. UBQLN2 mutations are rare in French and French-Canadian amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33(9):2230.e1-2230.e5.
117. Millecamps S., Corcia P., Cazeneuve C., et al. Mutations in UBQLN2 are rare in French amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33(4):839.e1-839.e3.
118. van Doormaal P.T., van Rheenen W., van Blitterswijk M., et al. UBQLN2 in familial amyotrophic lateral sclerosis in The Netherlands. Neurobiol Aging 2012, 33(9):2233.e7-2233.e8.
119. Williams K.L., Warraich S.T., Yang S., et al. UBQLN2/ubiquilin 2 mutation and pathology in familial amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33(10). 2527.e3-10.
120. Synofzik M., Maetzler W., Grehl T., et al. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol Aging 2012, 33(12):2949.e13-2949.e17.
121. Dillen L., Van Langenhove T., Engelborghs S., et al. Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients. Neurobiol Aging 2013, 34(6):1711.e1-1711.e5.
122. Brettschneider J., Van Deerlin V.M., Robinson J.L., et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 2012, 123(6):825-839.
123. Wu C.H., Fallini C., Ticozzi N., et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature 2012, 488(7412):499-503.
124. Ingre C., Landers J.E., Rizik N., et al. Anovel phosphorylation site mutation in profilin 1 revealed in a large screen of US, Nordic, and German amyotrophic lateral sclerosis/frontotemporal dementia cohorts. Neurobiol Aging 2012, 34(6):1708.e1-1708.e6.
125. Zou Z.Y., Sun Q., Liu M.S., et al. Mutations in the profilin 1 gene are not common in amyotrophic lateral sclerosis of Chinese origin. Neurobiol Aging 2013, 34(6):1713.e5-1713.e6.
126. Lattante S., Le Ber I., Camuzat A., et al. Mutations in the PFN1 gene are not a common cause in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration in France. Neurobiol Aging 2012, 34(6):1709.e1-1709.e2.
127. Daoud H., Dobrzeniecka S., Camu W., et al. Mutation analysis of PFN1 in familial amyotrophic lateral sclerosis patients. Neurobiol Aging 2013, 34(4):1311.e1-1311.e2.
128. Tiloca C., Ticozzi N., Pensato V., et al. Screening of the PFN1 gene in sporadic amyotrophic lateral sclerosis and in frontotemporal dementia. Neurobiol Aging 2013, 34(5). 1517.e9-10.
129. van Es M.A., Schelhaas H.J., van Vught P.W., et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 2011, 70(6):964-973.
130. Thiyagarajan N., Ferguson R., Subramanian V., et al. Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons. Nat Commun 2012, 3:1121.
131. Kirby J., Highley J.R., Cox L., et al. Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation. Neuropathol Appl Neurobiol 2013, 39(5):562-571.
132. Maruyama H., Morino H., Ito H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465(7295):223-226.
133. van Blitterswijk M., van Vught P.W., van Es M.A., et al. Novel optineurin mutations in sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging 2012, 33(5):1016.e1-1016.e7.
134. Del Bo R., Tiloca C., Pensato V., et al. Novel optineurin mutations in patients with familial and sporadic amyotrophic lateral sclerosis. JNeurol Neurosurg Psychiatry 2011, 82(11):1239-1243.
135. Iida A., Hosono N., Sano M., et al. Optineurin mutations in Japanese amyotrophic lateral sclerosis. JNeurol Neurosurg Psychiatry 2012, 83(2):233-235.
136. Watts G.D., Wymer J., Kovach M.J., et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004, 36(4):377-381.
137. Johnson J.O., Mandrioli J., Benatar M., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010, 68(5):857-864.
138. Koppers M., van Blitterswijk M.M., Vlam L., et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33(4). 837.e7-13.
139. DeJesus-Hernandez M., Desaro P., Johnston A., et al. Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS. Neurology 2011, 77(11):1102-1103.
140. Williams K.L., Solski J.A., Nicholson G.A., et al. Mutation analysis of VCP in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33(7):1488.e15-1488.e16.
141. Tiloca C., Ratti A., Pensato V., et al. Mutational analysis of VCP gene in familial amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33(3):630.e1-630.e2.
142. Chen Y.Z., Bennett C.L., Huynh H.M., et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004, 74(6):1128-1135.
143. Zhao Z.H., Chen W.Z., Wu Z.Y., et al. Anovel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009, 10(2):118-122.
144. Hirano M., Quinzii C.M., Mitsumoto H., et al. Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2011, 12(3):223-227.
145. Nishimura A.L., Mitne-Neto M., Silva H.C., et al. Amutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004, 75(5):822-831.
146. Kirby J., Hewamadduma C.A., Hartley J.A., et al. Mutations in VAPB are not associated with sporadic ALS. Neurology 2007, 68(22):1951-1953.
147. Conforti F.L., Sprovieri T., Mazzei R., et al. Sporadic ALS is not associated with VAPB gene mutations in Southern Italy. JNegat Results Biomed 2006, 5:7.
148. Chen H.J., Anagnostou G., Chai A., et al. Characterization of the properties of a novel mutation in VAPB in familial amyotrophic lateral sclerosis. JBiol Chem 2010, 285(51):40266-40281.
149. Kabashi E., El Oussini H., Bercier V., et al. Investigating the contribution of VAPB/ALS8 loss of function in amyotrophic lateral sclerosis. Hum Mol Genet 2013, 22(12):2350-2360.
150. Chow C.Y., Landers J.E., Bergren S.K., et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am J Hum Genet 2009, 84(1):85-88.
151. Mitchell J., Paul P., Chen H.J., et al. Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci USA 2010, 107(16):7556-7561.
152. Kim H.J., Kim N.C., Wang Y.D., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013, 495(7442):467-473.
153. Fecto F., Yan J., Vemula S.P., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011, 68(11):1440-1446.
154. Rubino E., Rainero I., Chio A., et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012, 79(15):1556-1562.
155. Hirano M., Nakamura Y., Saigoh K., et al. Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology 2013, 80(5):458-463.
156. Teyssou E., Takeda T., Lebon V., et al. Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol 2013, 125(4):511-522.
157. Puls I., Jonnakuty C., LaMonte B.H., et al. Mutant dynactin in motor neuron disease. Nat Genet 2003, 33(4):455-456.
158. Munch C., Sedlmeier R., Meyer T., et al. Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004, 63(4):724-726.
159. Chio A., Calvo A., Mazzini L., et al. Extensive genetics of ALS: a population-based study in Italy. Neurology 2012, 79(19):1983-1989.
160. Diekstra F.P., Saris C.G., van Rheenen W., et al. Mapping of gene expression reveals CYP27A1 as a susceptibility gene for sporadic ALS. PLoS One 2012, 7(4):e35333.
161. Elden A.C., Kim H.J., Hart M.P., et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010, 466(7310):1069-1077.
162. Lee T., Li Y.R., Ingre C., et al. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum Mol Genet 2011, 20(9):1697-1700.
163. Van Damme P., Veldink J.H., van Blitterswijk M., et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011, 76(24):2066-2072.
164. Ross O.A., Rutherford N.J., Baker M., et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet 2011, 20(16):3207-3212.
165. Soraru G., Clementi M., Forzan M., et al. ALS risk but not phenotype is affected by ataxin-2 intermediate length polyglutamine expansion. Neurology 2011, 76(23):2030-2031.
166. Daoud H., Belzil V., Martins S., et al. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch Neurol 2011, 68(6):739-742.
167. Gispert S., Kurz A., Waibel S., et al. The modulation of amyotrophic lateral sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis 2012, 45(1):356-361.
168. Gellera C., Ticozzi N., Pensato V., et al. ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol Aging 2012, 33(8):1847.e15-1847.e21.
169. Lahut S., Omur O., Uyan O., et al. ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One 2012, 7(8):e42956.
170. Chen Y., Huang R., Yang Y., et al. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol Aging 2011, 32(10):1925.e1-1925.e5.
171. Farg M.A., Soo K.Y., Warraich S.T., et al. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis. Hum Mol Genet 2013, 22(4):717-728.
172. Hart M.P., Gitler A.D. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications. JNeurosci 2012, 32(27):9133-9142.
173. van Es M.A., Veldink J.H., Saris C.G., et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009, 41(10):1083-1087.
174. Diekstra F.P., van Vught P.W., van Rheenen W., et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging 2012, 33(3):630.e3-630.e8.
175. Chio A., Mora G., Restagno G., et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol Aging 2013, 34(1):357.e1-357.e5.
176. Cronin S., Berger S., Ding J., et al. Agenome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet 2008, 17(5):768-774.
177. Del Bo R., Ghezzi S., Corti S., et al. DPP6 gene variability confers increased risk of developing sporadic amyotrophic lateral sclerosis in Italian patients. JNeurol Neurosurg Psychiatry 2008, 79(9):1085.
178. van Es M.A., van Vught P.W., Blauw H.M., et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet 2008, 40(1):29-31.
179. Cronin S., Tomik B., Bradley D.G., et al. Screening for replication of genome-wide SNP associations in sporadic ALS. Eur J Hum Genet 2009, 17(2):213-218.
180. Chio A., Schymick J.C., Restagno G., et al. Atwo-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 2009, 18(8):1524-1532.
181. Fogh I., D'Alfonso S., Gellera C., et al. No association of DPP6 with amyotrophic lateral sclerosis in an Italian population. Neurobiol Aging 2011, 32(5):966-967.
182. Li X.G., Zhang J.H., Xie M.Q., et al. Association between DPP6 polymorphism and the risk of sporadic amyotrophic lateral sclerosis in Chinese patients. Chin Med J (Engl) 2009, 122(24):2989-2992.
183. Kwee L.C., Liu Y., Haynes C., et al. Ahigh-density genome-wide association screen of sporadic ALS in US veterans. PLoS One 2012, 7(3):e32768.
184. Simpson C.L., Lemmens R., Miskiewicz K., et al. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet 2009, 18(3):472-481.
185. Mustfa N., Walsh E., Bryant V., et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology 2006, 66(8):1211-1217.
186. Lechtzin N., Scott Y., Busse A.M., et al. Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph Lateral Scler 2007, 8(3):185-188.
187. Spataro R., Ficano L., Piccoli F., et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. JNeurol Sci 2011, 304(1-2):44-48.
188. Traynor B.J., Alexander M., Corr B., et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. JNeurol Neurosurg Psychiatry 2003, 74(9):1258-1261.